Medpace Holdings, Inc. MEDP Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $497.05M-25.8% | $669.44M+173% | $245.45M+768% | $28.27M-93.9% | ||
| $402.08M+35.6% | $296.44M-0.7% | $298.4M+17.8% | $253.4M+35.9% | ||
| $989.62M-3.8% | $1.03B+73.3% | $593.83M+77.8% | $333.96M-51.7% | ||
| $131.06M+6.0% | $123.62M+2.5% | $120.59M+9.8% | $109.85M+17.9% | ||
| $662.4M0.0% | $662.4M0.0% | $662.4M0.0% | $662.4M0.0% | ||
| $1.77M-94.8% | $34.37M-4.0% | $35.81M-5.8% | $38.01M-8.1% | ||
| $1.98B-6.0% | $2.1B+26.8% | $1.66B+22.5% | $1.35B-18.5% | ||
| $28.14M-13.5% | $32.53M+2.1% | $31.87M-3.6% | $33.07M+28.8% | ||
| $854.39M+20.2% | $710.59M+26.9% | $559.86M+21.0% | $462.73M+34.3% | ||
| $1.34B+21.7% | $1.1B+19.4% | $925.13M+15.1% | $803.47M+44.2% | ||
| $1.52B+18.9% | $1.28B+16.2% | $1.1B+13.6% | $966.11M+36.6% | ||
| 250M+81,599% | 306K-0.6% | 308K-0.3% | 309K-14.2% | ||
| -$459.98M-5,732% | $8.17M+104% | -$221.65M+38.4% | -$359.83M-253% | ||
| $459.07M-44.4% | $825.55M+47.7% | $558.95M+44.7% | $386.39M-59.5% | ||
| $1.98B-6.0% | $2.1B+26.8% | $1.66B+22.5% | $1.35B-18.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Medpace Holdings, Inc.'s total assets?
- Medpace Holdings, Inc. (MEDP) holds $2.1B in total assets, up 12.2% year over year.
- How much debt does Medpace Holdings, Inc. have?
- Medpace Holdings, Inc. carries $146.1M in total debt against $598.3M of shareholders' equity, a debt-to-equity ratio of 0.24.
- How much cash does Medpace Holdings, Inc. have?
- Medpace Holdings, Inc. holds $652.7M in cash and equivalents.
- Can Medpace Holdings, Inc. cover its short-term obligations?
- Its current ratio is 0.85 — current liabilities exceed current assets.
- Where does Medpace Holdings, Inc.'s balance sheet data come from?
- Every line is extracted from Medpace Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
